Information Provided By: 
Fly News Breaks for January 22, 2018
DVAX
Jan 22, 2018 | 07:59 EDT
RBC Capital analyst Brian Abrahams upgraded Dynavax to Outperform from Speculative Risk with a slightly lower price target of $27 vs. $28 prior. Abrahams says the rating revision is based on his meeting with the management that gave better visibility on Heplisav-B launch, adding that shares appear undervalued over the long term given the low-risk and steady revenue stream of the treatment.
News For DVAX From the Last 2 Days
There are no results for your query DVAX
